0001193125-26-222904
SEC filingQ1 2026 operating loss widened to -$16.3M (-100.3% YoY) as clinical development costs escalated for aglatimagene programs, driving net loss of -$8.9M and free cash flow burn of -$18.7M despite existing liquidity supporting operations into Q1 2028.
Net income swung to a -$8.9 million loss from a $7.4 million profit YoY, yielding diluted EPS of -$0.14 versus $0.13. The shift highlights non-operating volatility but aligns with the company's history of significant operating losses since inception, as it has generated no revenue from product sales. Prior losses and expected future losses continue to pressure stockholders' equity and working capital, a noted risk factor.
Despite intensified cash usage, management affirms that existing cash and cash equivalents as of March 31, 2026, will fund operating expenses and capital requirements into the first quarter of 2028. This liquidity position provides a multi-year runway, enabling sustained focus on aglatimagene and other programs without near-term revenue. Looking forward, expenses are expected to increase with headcount expansion for clinical development, manufacturing, and compliance needs, reinforcing the need for disciplined capital management amid ongoing losses.